Chronic Kidney Disease Drugs Market - Global Size, Share, Trends, Growth and Forecast Year ( 2022 – 2032 )

Chronic Kidney Disease Drugs Market

Chronic Kidney Disease Drugs Market: Size & Share by (By Drug Class, Route of Administration, By Distribution Channel and Region) and Forecast Year 2023-2032.

Chronic Kidney Disease Drugs Market + Report Scope (by Share & Size)

The global Chronic Kidney Disease Drugs market is expected to grow significantly in the forecast period of 2023 to 2032. KD Market Research analyses that the market is growing with a CAGR of 4.6% in the forecast period of 2023 to 2032 and is expected to reach USD 19.09 Billion by 2032. The increasing prevalence of kidney disease is the major factor driving the Chronic Kidney Disease Drugs market's growth. Global Chronic Kidney Disease Drugs Market, by Drug Class (ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), B-Blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, and others), by Route of Administration (Oral, Subcutaneous, Intravenous), by Patient Type (Dialysis, Others) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). - Industry Trends and Forecast to 2032.

Chronic Kidney Disease Drugs Market Definition & Overview

Chronic kidney disease (CKD) is a long-term condition in which the kidneys gradually lose their ability to function properly. It is typically a progressive disease that develops over a period of months or years. CKD is characterized by the accumulation of waste products and fluid imbalances in the body. Early stages of CKD may not exhibit noticeable symptoms, but as the disease progresses, individuals may experience fatigue, swelling, changes in urination, decreased appetite, nausea, and high blood pressure. Diagnosis involves blood and urine tests, imaging studies, and sometimes kidney biopsy. Chronic kidney disease (CKD) drugs encompass a range of medications and therapies that are used in the treatment and management of CKD. These drugs aim to slow the progression of the disease, manage symptoms, and prevent complications.

The KD Market Research team has developed a comprehensive market research report on a global basis on the Chronic Kidney Disease Drugs Market, with a focus on identifying the market trends and drivers, Key companies, constraints and challenges, competitive landscape, customer insights, future outlook, and regulatory environment business owners face. The research report includes market segmentation types and future outlook, a regional perspective, and an analysis of recent Chronic Kidney Disease Drugs Market developments.

Moreover, it provides detailed information on the base year and forecast year market size, global and regional market share, industry developments, and customer insights, as well as SWOT analysis, Porter's five forces analysis, PESTEL analysis, heat map analysis, market forecast, and major key players operating in the Chronic Kidney Disease Drugs Market

Chronic Kidney Disease Drugs Market Insights

Chronic Kidney Disease Drugs Market Dynamics Growth Drivers and Challenges

Chronic Kidney Disease Drugs Market Opportunities that Trigger Market Growth

• Increasing Prevalence of Chronic Kidney Disease – The global chronic kidney disease (CKD) drugs market is primarily driven by the increasing prevalence of CKD worldwide. The rising number of patients diagnosed with CKD is creating a significant demand for medications and therapies to manage the disease. CKD is a growing public health concern, with risk factors such as diabetes and hypertension on the rise. This has led to a greater focus on the development and availability of CKD drugs to meet the treatment needs of the growing patient population.

• Rising Geriatric Population – The increasing number of elderly individuals and their susceptibility to kidney disorders are expected to drive the demand for chronic kidney disease (CKD) drugs. Many older adults face challenges in performing basic functions due to kidney issues, and while dialysis provides temporary relief, there is a need for drugs that can support patients who are unable to undergo timely dialysis. Moreover, CKD can also affect younger individuals, causing pain and discomfort. Consequently, the use of CKD drugs is anticipated to rise among this population.

• Advancements in drug development - Advancements in drug development: Ongoing research and development efforts have led to the introduction of new and improved CKD drugs. Pharmaceutical companies are investing in developing innovative therapies that target specific mechanisms involved in CKD progression, aiming to slow disease progression and improve outcomes for patients. Furthermore, Advancements in diagnostic tools, such as biomarker-based tests and imaging techniques, aid in early detection and monitoring of CKD. This facilitates timely intervention and the prescription of appropriate CKD drugs.

Chronic Kidney Disease Drugs Market Hurdles and Challenges

• Increase in preference for generic drug variants– The increasing preference for generic drug variants poses a restraint on the growth of the chronic kidney disease (CKD) drugs market. The rising demand for cost-effective treatment options leads to higher adoption of generic CKD drugs over branded counterparts. Generic drugs, being more affordable and often bioequivalent, offer a competitive advantage. This preference reduces the market share and revenue potential for branded CKD drugs, limiting their growth opportunities in the market.

• Lack of awareness and screening programs– The lack of awareness and screening programs for chronic kidney disease (CKD) is expected to hinder the growth of the global CKD drugs market. Limited awareness among the general population and healthcare providers leads to delayed diagnosis and suboptimal management. Insufficient screening programs for high-risk populations impede early detection and intervention. However, earlier diagnosis of CKD has the potential to slow disease progression, prevent complications, and improve outcomes.

• Competition from biosimilars due to patent loss– Competition from biosimilars, which are lower-cost alternatives to originator drugs, poses a significant restraint on the growth of the chronic kidney disease (CKD) drugs market. As biosimilars enter the market after the loss of patent protection, they can compete with original CKD drugs, leading to potential market share loss for pharmaceutical companies. To mitigate this, companies invest in R&D, innovation, and strategic pricing to maintain their competitive edge.

Chronic Kidney Disease Drugs Market Segmentation, Division and Categorization

• By Drug Class: ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), B-Blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, Others
• By Route of Administration: Oral, Subcutaneous, Intravenous
• By Patient Type: Dialysis, Others
• By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• Region: North America, Europe, Asia-Pacific, Latin America, Middle East and Africa

Chronic Kidney Disease Drugs Market Industry Developments

Several industry developments have taken place in the chronic kidney disease (CKD) drugs market. In April 2022, AstraZeneca revealed plans to establish a strategic R&D center and Alexion headquarters in Cambridge, Massachusetts. This expansion aims to foster collaboration and innovation by being in close proximity to esteemed academic, pharmaceutical, and biotech institutions, providing access to potential talent.

In May 2022, NetVation DL Medicine announced a research collaboration with Pfizer Inc. The collaboration involves utilizing HitGen's DNA-encoded libraries to validate early targets, identify novel chemical substances, and optimize leads, thereby driving advancements in CKD drug research.

In March 2019, Aster Hospitals, a leading private healthcare service provider in the GCC states, launched an initiative to raise awareness and promote the prevention of CKD. The initiative focuses on educating the public, creating awareness about CKD, and facilitating early diagnosis to prevent the progression of the disease.

These industry developments highlight the commitment of major players in the CKD drugs market towards research, collaboration, awareness, and expansion. These efforts aim to drive innovation, improve patient outcomes, and address the challenges associated with CKD. The establishment of research centers, collaborations with industry partners, acquisitions, and awareness initiatives collectively contribute to the growth and advancement of the CKD drugs market.

Chronic Kidney Disease Drugs Market Key Featured Companies

• AstraZeneca,
• Pfizer Inc.
• Amgen Inc.
• FibroGen, Inc.
• Kissei Pharmaceutical Co. Ltd
• Keryx Biopharmaceuticals, Inc.
• GlaxoSmithKline plc.
• F. Hoffmann-La Roche
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.

In May 2022, Pfizer Inc. announced positive Phase 3 trial results for tofacitinib, showing significant improvement in kidney function for patients with lupus nephritis, a complication of CKD. This offers a potential treatment option for CKD patients.

These companies are actively involved in developing and providing innovative diagnostic tests, platforms, and technologies for chronic kidney disease detection. Their contributions likely include advancements in accuracy, speed, automation, and convenience to improve diagnostic outcomes and patient care.

Chronic Kidney Disease Drugs Market Regional Analysis

North America's dominance in the chronic kidney disease (CKD) drugs market is attributed to the fact that most CKD drug manufacturers are located in the region. The United States commands a substantial portion of the chronic kidney disease (CKD) drugs market due to the high prevalence of CKD, extensive testing and screening efforts, and a well-established healthcare system. Asia Pacific region is also growing at a rapid pace owing to the large kidney disease patient population and increasing awareness about the disease.  The Europe Chronic Kidney Disease (CKD) drugs market is a significant segment within the global pharmaceutical industry. Europe, consisting of countries such as Germany, France, the United Kingdom, Italy, and Spain, has a well-developed healthcare infrastructure and a high prevalence of CKD among its population.